| Literature DB >> 35142581 |
Raheel Sufian Siddiqui1,2, Sibgha Gull Chaudhary1, Moazzam Shahzad1,3, Iqra Anwar1, Ali Hussain1, Nausheen Ahmed1, Sunil Hari Abhyankar1, Leyla Shune1, Peiman Hematti4, Heather Male1, Faisal Khosa5, Tara Lin1, Joseph Patrick McGuirk1, Natalie Scott Callander4, Muhammad Umair Mushtaq1.
Abstract
We investigated gender inequality in the National Institutes of Health (NIH) funding for hematologic malignancies and cellular therapies (HMCT). The data were retrieved from the NIH Research Portfolio Online Reporting Tools (RePORT). In 2018-2019, 1834 grants totaling $799 million were awarded (men 71% vs. women 29%) to 975 principal investigators (PIs), including 680 (70%) male PIs and 295 (30%) female PIs. There was no significant gender difference in the mean grant amount per PI. Male PIs as compared to female PIs had a higher h-index (44 vs 31, p < 0.001), a higher number of publications (159.5 vs 94, p < 0.001), and higher years of active research (26 vs 21, p < 0.001). In multivariate analyses, a higher h-index independently predicted a higher mean grant amount per PI (p = 0.010), and female PIs were independently less likely to have a higher h-index (p < 0.001). Our study shows significant gender disparity in the NIH funding for HMCT research.Entities:
Keywords: Hematologic malignancies; cellular therapies; gender disparities; research funding
Mesh：
Year: 2022 PMID： 35142581 DOI： 10.1080/10428194.2022.2038378
Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022